Anna Halpern, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Bayer
    Topic:
    research contract
    Date added:
    05/27/2022
    Date updated:
    10/20/2023
    Relationship end date:
    08/31/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Jazz pharmaceuticals
    Topic:
    research contract
    Date added:
    05/27/2022
    Date updated:
    10/20/2023
    Relationship end date:
    10/22/2022
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Imago Biosciences
    Topic:
    research contract
    Date added:
    05/27/2022
    Date updated:
    10/20/2023
    Relationship end date:
    08/31/2026
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Gilead Sciences
    Topic:
    research contract
    Date added:
    05/27/2022
    Date updated:
    10/20/2023
    Relationship end date:
    12/31/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Karyopharm Therapeutics
    Topic:
    research contract
    Date added:
    05/27/2022
    Date updated:
    10/20/2023
    Relationship end date:
    10/31/2026
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Incytes Pharmaceuticals
    Topic:
    research contract
    Date added:
    05/27/2022
    Date updated:
    10/20/2023
    Relationship end date:
    12/31/2026
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Notable Labs
    Topic:
    consulting
    Date added:
    05/27/2022
    Date updated:
    10/20/2023
    Relationship end date:
    04/06/2022
Return to Best of ASH & SABCS 2024, Portland